Acne Medicine Market Trends, Insights, and Growth Analysis

The global acne medicine market, valued at US$ 13.44 billion in 2023, is expected to grow to US$ 23.33 billion by 2034, with a CAGR of 5.14%. The rise in skin conditions due to factors like poor diet, lack of exercise, and hormonal imbalances is driving innovations in treatments and boosting market growth.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5309?

Acne Medicine Market Trends

The American Academy of Dermatology’s Good Skin Knowledge Community Grant Program provides a comprehensive, four-module lesson plan for children aged 8-13, teaching them about skin health, acne, and sun safety in both English and Spanish. The program offers funding of $20 per child, with a minimum of 20 children ($400) and a maximum of $2,000 for up to 100 children.

The Spironolactone for Adult Female Acne (SAFA) Research Study, funded by the National Institute for Health and Care Research (NIHR), is the first large-scale clinical trial to demonstrate that spironolactone is an effective treatment for acne.

In August 2023, Zydus LifeSciences received approval from the US Food and Drug Administration (USFDA) to market a generic acne treatment in the United States. Additionally, the company received final approval for its Isotretinoin capsules USP.

According to IQVIA MAT data, annual sales of isotretinoin capsules in the US reached $165 million in 2023.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

Segmental Insights

Therapeutic Class Insights In 2023, the retinoid segment led the global acne medicine market due to its widespread use and proven effectiveness in treating acne. Retinoids work by preventing pore blockages and reducing inflammation, which are key factors in acne development. These treatments are commonly found in creams, gels, and lotions, making them suitable for all skin types. Popular retinoids such as retinol, tretinoin, adapalene, and tazarotene are frequently used to treat acne, fine lines, and hyperpigmentation. Dermatologists typically prescribe them for mild to moderate acne.

Formulation Insights Topical medications dominated the acne medicine market in 2023, as creams, gels, and lotions are easy to apply to affected areas. Besides retinoids, antibiotics like erythromycin and clindamycin are also used topically for acne treatment. Combining these antibiotics with benzoyl peroxide and topical retinoids helps prevent bacterial resistance and provides effective treatment that can last from weeks to years.

Type Insights The prescription medicine segment was the leader in 2023, as these products contain higher levels of active ingredients and more advanced formulations. Oral antibiotics like azithromycin, tetracycline, and roxithromycin are often prescribed for acne that doesn’t respond to topical treatments. Hormonal therapies, such as oral contraceptives, are also used to treat acne, especially in adults, adolescents, and women, by reducing sebum production.

Acne Type Insights Non-inflammatory acne was the dominant type in 2023, affecting a large portion of the population, particularly adolescents and young adults. Acne vulgaris, a common skin disorder, can include both inflammatory and non-inflammatory lesions. Blackheads and whiteheads are common forms of non-inflammatory acne that don’t cause inflammation or swelling.

Distribution Channel Insights The pharmacy and drug store segment led the acne medicine market in 2023 due to the growing number of accessible pharmacies and drug stores. These locations are convenient for consumers to purchase acne treatments, some of which are available without a prescription, making them even more accessible.

Recent Developments by Bausch Health Companies Inc. In April 2024, Bausch Health Companies Inc. launched PrARAZLO (tazarotene lotion, 0.045%), a topical prescription treatment for acne vulgaris, available through BC PharmaCare in British Columbia's public drug program. In October 2023, the U.S. Food and Drug Administration approved CABTREO (clindamycin phosphate, adapalene, and benzoyl peroxide) Topical Gel for the treatment of acne vulgaris in patients aged 12 and older. This makes Cabtreo the first FDA-approved triple combination treatment for acne in a fixed-dose formulation.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field -? https://www.towardshealthcare.com/table-of-content/acne-medicine-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5309

You can place an order or ask any questions, please feel free to contact us at [email protected]

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

For Latest Update Follow Us: https://www.dhirubhai.net/company/towards-healthcare